The latest research findings of BCMA CAR-T therapy for multiple myeloma in 2023 | Equecabtagene Autoleucel (FUCASO®) IASO Bio and Innovent presented their latest research findings on the Equecabtagene Autoleucel injection (brand name: FUCASO®) for multiple myeloma at the 2023 American Society of Hematology (ASH) Annual Meeting. This study was primarily based on Read More
CAR-T
Eque-cel brings new treatment prospects for multiple myeloma. From December 9th to 12th, the Annual American Society of Hematology Meeting (ASH 2023) was held in San Diego, USA. At this conference, the FUMANBA-1 study, led by Professors Chunrui Li from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, and Lugui Read More
Whether it’s multiple treatment failures or recurrent tumors with systemic metastasis, miraculous remissions are still achieved after undergoing treatment! Chinese CAR-T therapy has brought a brand-new hope for various late-stage cancers such as gastric, colorectal, pancreatic, and liver cancers. The renowned CAR-T therapy is almost universally recognized, and its successful development has instilled hope for Read More
BCMA CAR-T FUCASO On June 30, 2023,China National Medical Products Administration(NMPA) has approved the New Drug Application (NDA) for FUCASO(Equecabtagene Autoleucel, co-developed and co-commercialized by IASO Bio and Innovent, IASO Bio R&D code: CT103A, Innovent R&Dcode: IBI326) the world’s first fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or Read More
Liver cancer is a heavy burden for Chinese people. Data released by the International Agency for Research on Cancer (IARC) last year showed that in China, there are over 410,000 new cases of liver cancer and over 390,000 deaths due to liver cancer each year, accounting for 45.3% and 47.1% of the global total, respectively. Read More
Two patients with advanced liver cancer, who had multiple treatment failures, relapses, and rapid progression, have achieved complete tumor remission after receiving a new type of immunotherapy! More excitingly, recent follow-ups at a well-known tumor center in Shanghai confirmed that their tumors have been in complete remission for 7 and 8 years, respectively! This means Read More
On November 8, 2023, we have received another major piece of good news! According to the official website of the National Medical Products Administration (NMPA) of China, the new drug application (NDA) for Inaticabtagene Autoleucel Injection (CNCT19 Cell Injection), a CAR-T therapy product developed by Hegen Biotech, has been officially approved for market. This therapy Read More
Two long-term disease-free survival cases of advanced liver cancer treated with CAR-GPC3 T cell therapy developed by Chinese scientists were published in the internationally renowned immunology journal Cancer Communications. One of the patients has achieved complete remission of the tumor for 8 years, which is a major breakthrough in China’s anti-cancer research. This therapy is Read More
Dr Richard Quek, Senior Consultant, Medical Oncology, explains 5 things you need to know about sarcoma, one of the rarest forms of cancer. Sarcoma is a rare form of cancer that affects the bones, connective tissues of the body, and areas such as blood vessels, muscle, nerves and fat. It is a complex and diverse disease, with Read More
Leukaemia means cancer of blood cells. It can be classified into two main categihgffddjories: AcuteppppmmpppjjjjLeukaemias and other types of Leukaemias. In this issue of HealthNews, we break down the types of Leukaemia and how advances in treatment are improving the survival outlook for patients with the disease. Leukaemia is a type of blood cancer that Read More
They may sound similar, but Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are two distinct types of lymphoma, each with unique disease characteristics. In this issue of HealthNews, we look at some of the key differences between them. Lymphoma is a type of blood cancer that begins in the lymphatic system—a network of vessels, nodes, and ducts throughout the Read More
Chimeric Antigen Receptor (CAR) T-cell Therapy has been hailed as the next frontier of oncology, as it is an innovative and revolutionary approach to treating cancers. Here is a look at how the treatment has evolved from the past into the present, and towards the future. As its name suggests, CAR T-cell Therapy is a type Read More